MedTrace Logo

Safety and Effectiveness of No-touch Technique for Ascending Aorta in MICS-CABG

NCT07172620 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 260

Last updated 2025-09-15

No results posted yet for this study

Summary

The goal of this single-center prospective cohort study is to compare perioperative safety metrics and follow-up survival analyses in patients receiving Minimally Invasive Cardiac Surgery Coronary Artery Bypass Grafting(MICS-CABG) and Off-Pump Coronary Artery Bypass(OPCAB). The main question it aims to answer is:

Is the bridge vessel patency rate of patients in the MICS-Notouch group noninferior to that of a saphenous vein bridge with conventional open-chest bypass?

Participants will be divided into two groups:

Exposure group (MICS-Notouch group): non-extracorporeal circulation multiple coronary artery bypass grafting surgery performed under direct visualization of a small incision in the left chest, including the application of LIMA (left internal mammary artery) + SVG (saphenous vein) multiple bypass grafting.

Control group (OPCAB group): conventional median chest opening, non-extracorporeal circulation multi-branch coronary artery bypass graft surgery.

Conditions

  • Coronary Artery Bypass Grafting
  • Off-pump Coronary Artery Bypass
  • Minimally Invasive Cardiac Surgery
  • Coronary Arterial Disease (CAD)

Interventions

PROCEDURE

Non-extracorporeal multiple coronary artery bypass graft (CABG) performed under direct visualization through a small incision in the left side of the chest.

Exposure group (MICS-Notouch group): Direct visualization non-extracorporeal coronary artery bypass grafting with a small left chest incision, including the use of LIMA (left internal mammary artery) + SVG (saphenous vein) multibranch bypass grafting.

PROCEDURE

Multi-branch coronary artery bypass grafting with conventional median open heart and off-pump circulation

Control Group (OPCAB Group): Conventional median open multiple coronary artery bypass grafting with extracorporeal circulation.

Sponsors & Collaborators

  • Peking University Third Hospital

    lead OTHER

Principal Investigators

  • Ling Yunpeng, PhD · Peking University Third Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-01
Primary Completion
2026-12-31
Completion
2030-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07172620 on ClinicalTrials.gov